论文部分内容阅读
目的:探究甲氨蝶呤+来氟米特联合沙利度胺在类风湿关节炎(rheumatoid arthritis,RA)治疗中的临床效果。方法:选取类风湿性关节炎(RA)患者68例作为研究对象,将其随机分为A组(30例)和B组(38例),A组采用甲氨蝶呤+来氟米特治疗,B组则采用甲氨蝶呤与来氟米特联合沙利度胺治疗,两组患者均持续接受治疗半年;对患者治疗前后的关节肿胀个数、关节压痛个数、CRP(C反应蛋白)、ESR(血沉)、RF(类风湿因子)等指标以及治疗有效率等进行测定、统计。结果:两组患者接受治疗后的各指标较治疗前均有明显改善(P<0.05),且B组各项指标的改善情况优于A组,差异显著,具有统计学意义(P<0.05);两组患者在治疗期间均无明显的不良反应出现。结论:甲氨蝶呤与来氟米特联合沙利度胺治疗类风湿关节炎疗效确切,能够改善患者的各项指标,安全可靠,值得临床推广应用。
Objective: To investigate the clinical effect of methotrexate + leflunomide combined with thalidomide in the treatment of rheumatoid arthritis (RA). Methods: Sixty-eight patients with rheumatoid arthritis (RA) were enrolled in this study. They were randomly divided into group A (30 cases) and group B (38 cases). Group A was treated with methotrexate and leflunomide , B group was treated with methotrexate and leflunomide combined with thalidomide, two groups of patients continued to receive treatment for six months; the number of patients before and after treatment of joint swelling, joint tenderness, CRP (C-reactive protein ), ESR (erythrocyte sedimentation rate), RF (rheumatoid factor) and other indicators as well as the treatment efficiency and other measurements and statistics. Results: After treatment, the indexes in both groups were significantly improved (P <0.05), and the improvement of each index in group B was better than that in group A, with significant difference (P <0.05) There were no obvious adverse reactions in both groups during the treatment. Conclusion: Methotrexate and leflunomide combined with thalidomide treatment of rheumatoid arthritis curative effect is accurate, can improve the patient’s indicators, safe and reliable, it is worth clinical application.